 |
| Anno I | Numero 6 | Ottobre 2016 |
| Comitato scientifico editoriale: Sergio Bracarda, Giacomo Cartenì, Giuseppe Procopio Editore: Intermedia – Direttore Responsabile: Mauro Boldrini |
| Notizie dalla ricerca |
| Programmed cell death-1 pathway inhibitors in genitourinary malignancies: specific side-effects and their management |
| Immune checkpoint inhibitors such as those that target the programmed cell death (PD)-1 pathway harness the host immune system to elicit an antitumor response. Their remarkable clinical benefit has led to regulatory approvals in several malignancies including the genitourinary cancers, renal cell carcinoma, and urothelial carcinoma. This review will focus on the management of the toxicities encountered with these agents. Although generally well tolerated, a small proportion of patients … |
| Continua a leggere |
| The prospect of precision therapy for renal cell carcinoma |
| The therapeutic landscape of renal cell carcinoma (RCC) has greatly expanded in the last decade. From being a malignancy orphan of effective therapies, kidney cancer has become today a tumor with several treatment options. Renal cell carcinoma (RCC) is a metabolic disease, being characterized by the dysregulation of metabolic pathways involved in oxygen sensing (VHL/HIF pathway alterations and the subsequent up-regulation of HIF-responsive genes such as VEGF, PDGF, EGF, and glucose … |
| Continua a leggere |
| Immunobiology and immunotherapy in genitourinary malignancies |
| Immunotherapy has traditionally been a critical component of the cancer treatment armamentarium in genitourinary (GU) cancers. It has an established role in the management of carefully selected patients with metastatic renal cell carcinoma (RCC) [e.g., high dose interleukin-2 (IL-2)] and non-muscle invasive bladder cancer (NMIBC) [e.g., intravesical Bacillus Calmette-Guérin (BCG)]. In 2010, the sipuleucel-T vaccine was approved by the FDA for the management of metastatic castration-resistant … |
| Continua a leggere |
| The Intratumoral Balance between Metabolic and Immunologic Gene Expression Is Associated with Anti-PD-1 Response in Patients with Renal Cell Carcinoma |
| Pretreatment tumor PD-L1 expression has been shown to correlate with response to anti-PD-1/PD-L1 therapies. Yet, most patients with PD-L1+ tumors do not respond to treatment. The current study was undertaken to investigate mechanisms underlying the failure of PD-1-targeted therapies in patients with advanced renal cell carcinoma (RCC) whose tumors express PD-L1. Formalin-fixed, paraffin-embedded pretreatment tumor biopsies expressing PD-L1 were derived from 13 RCC … |
| Continua a leggere |
| PD-1/PD-L1 expression in chromophobe renal cell carcinoma: An immunological exception? |
| Immune checkpoint inhibitors targeting the inhibitory cross talk between tumor and immune cells have been approved for therapy in renal cell carcinoma (RCC). In contrast to clear cell RCC, little is known on PD-1/PD-L1 expression patterns in rarer RCC subtypes. The aim of this study was to evaluate the prevalence, distribution and prognostic impact of PD-1 and PD-L1 expression in chromophobe (ch)RCC. Patients who underwent renal surgery due to chRCC were retrospectively evaluated. Tumor specimen was … |
| Continua a leggere |
| Appuntamenti AIOM |
| XVIII Congresso Nazionale AIOM |
| Roma, 28 – 30 ottobre 2016 |
| Link all'evento |
| Hot Topics in Oncologia 2016 |
| Fiuggi (FR), 22 ottobre 2016 |
| Dialoghi sull'Immunoterapia dei Tumori dell'AIOM Campania |
| Salerno, 25 ottobre 2016 |
| Dialoghi sull'Immunoterapia dei Tumori dell'AIOM Campania |
| Avellino, 3 novembre 2016 |
| 4th International Conference 'Translational Research in Oncology' |
| Meldola (FC), 8 novembre 2016 Forlì, 9 – 11 novembre 2016 |
| Immuno-Oncologia: Stato dell'Arte e Update |
| Cagliari, 9 novembre 2016 |
| IV Meeting Uro-Oncologico: Update 2016 sui tumori urologici |
| Fano (PU), 11 – 12 novembre 2016 |
| Nuove Frontiere Diagnostico-Terapeutiche nelle Neoplasie Polmonari, Renali e nel Melanoma |
| Varese, 12 novembre 2016 |
| 5th World Top Communications of the Year in Genito-Urinary Oncology |
| Arezzo, 17 – 18 novembre 2016 |
| Conferenza Annuale SIOG 2016 Geriatric Oncology: a multidisciplinary approach in a global environment |
| Milano, 17 – 19 novembre 2016 |
| Coniugare Innovazione, Sostenibilità e Continuità di Cura in Oncologia Il Ruolo delle Reti Regionali |
| Milano, 19 novembre 2016 |
| First International Congress Clinical Needs and Translational Research in Oncology |
| Reggio Emilia, 28 – 29 novembre 2016 |
| Immunotherapy Bridge 2016 |
| Napoli, 30 novembre 2016 |
| Questi e altri appuntamenti si possono consultare sul sito AIOM www.aiom.it |
| Editore: Intermedia s.r.l. – Via Malta 12/b, 25124 Brescia – tel. 030 226105 fax 030 2420472 – Reg. Trib. di Brescia n. 35/2001 del 2/7/2001 Per contattare la redazione e commentare le notizie clicca qui: redazione Per consultare i numeri arretrati della newsletter clicca qui: archivio Per sospendere la ricezione di questa newsletter clicca qui: AIOM news RIMUOVI |
Questo progetto è stato realizzato con il contributo di  |